Drug Profile
Research programme: anti-cancer and anti-infective therapeutics - Evolva Holdings SA
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Evolva Holding SA; Roche
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Cancer in Switzerland
- 04 Nov 2017 No recent reports of development identified for research development in Infections in Switzerland
- 29 Aug 2012 Early research is ongoing in Switzerland